Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function

Eri Muso, Soichi Sakai, Youske Ogura, Susumu Yukawa, Yoshiki Nishizawa, Noriaki Yorioka, Takao Saito, Masatoshi Mune, Satoshi Sugiyama, Yasuhiko Iino, Tsutomu Hirano, Motoshi Hattori, Tsuyoshi Watanabe, Hitoshi Yokoyama, Hiroshi Sato, Shunya Uchida, Takashi Wada, Tetsuo Shoji, Hiroaki Oda, Kiyoshi MoriHideki Kimura, Osamu Ito, Akira Nishiyama, Shoichi Maruyama, Reiko Inagi, Shoichi Fujimoto, Tatsuo Tsukamoto, Yusuke Suzuki, Hirokazu Honda, Tetsuya Babazono, Kazuhiko Tsuruya, Yukio Yuzawa

Research output: Contribution to journalArticlepeer-review

Abstract

Many reports have shown the therapeutic efficacy of LDL apheresis (LDL-A) in drug-resistant nephrotic syndrome (NS) for improvement of heavy proteinuria and severely impaired renal function. To obtain comprehensive results in a large number of cases, a post hoc analysis of the Prospective Observational survey on the Long-Term Effects of the LDL-Apheresis on the Drug Resistant Nephrotic Syndrome (POLARIS) study was performed by stratifying enrolled cases according to the pretreatment estimated glomerular filtration rate (eGFR) levels indicating normal (N) (≥60 ml/min/1.73 m2), moderately impaired (M) (≥30 to <60 ml/min/1.73 m2), and severely impaired (S) (<30 ml/min/1.73 m2) renal function. Significant improvements of proteinuria and renal function were found in Group N and, most interestingly, in Group M. A tendency for improvement in proteinuria was found in Group S. Most cases in all groups had not entered end-stage renal disease at 2 years after LDL-A treatment. These results suggest that LDL-A has therapeutic efficacy even in cases in which renal function has declined to 30 ml/min/1.73 m2.

Original languageEnglish
Pages (from-to)220-228
Number of pages9
JournalTherapeutic Apheresis and Dialysis
Volume26
Issue number1
DOIs
Publication statusAccepted/In press - 2021

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Fingerprint

Dive into the research topics of 'Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function'. Together they form a unique fingerprint.

Cite this